JP2023156274A5 - - Google Patents
Info
- Publication number
- JP2023156274A5 JP2023156274A5 JP2023106553A JP2023106553A JP2023156274A5 JP 2023156274 A5 JP2023156274 A5 JP 2023156274A5 JP 2023106553 A JP2023106553 A JP 2023106553A JP 2023106553 A JP2023106553 A JP 2023106553A JP 2023156274 A5 JP2023156274 A5 JP 2023156274A5
- Authority
- JP
- Japan
- Prior art keywords
- present specification
- invention described
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562253896P | 2015-11-11 | 2015-11-11 | |
| US62/253,896 | 2015-11-11 | ||
| JP2018524218A JP7841838B2 (ja) | 2015-11-11 | 2016-11-09 | ミオスタチンアンタゴニストの使用、それを含有する組合せ物およびその使用 |
| PCT/IB2016/056744 WO2017081624A1 (en) | 2015-11-11 | 2016-11-09 | Uses of myostatin antagonists, combinations containing them and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524218A Division JP7841838B2 (ja) | 2015-11-11 | 2016-11-09 | ミオスタチンアンタゴニストの使用、それを含有する組合せ物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023156274A JP2023156274A (ja) | 2023-10-24 |
| JP2023156274A5 true JP2023156274A5 (enExample) | 2026-04-02 |
Family
ID=57321372
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524218A Active JP7841838B2 (ja) | 2015-11-11 | 2016-11-09 | ミオスタチンアンタゴニストの使用、それを含有する組合せ物およびその使用 |
| JP2023106553A Pending JP2023156274A (ja) | 2015-11-11 | 2023-06-29 | ミオスタチンアンタゴニストの使用、それを含有する組合せ物およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524218A Active JP7841838B2 (ja) | 2015-11-11 | 2016-11-09 | ミオスタチンアンタゴニストの使用、それを含有する組合せ物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11357851B2 (enExample) |
| EP (1) | EP3373927A1 (enExample) |
| JP (2) | JP7841838B2 (enExample) |
| KR (1) | KR102764084B1 (enExample) |
| CN (1) | CN109069467B (enExample) |
| AU (4) | AU2016352806A1 (enExample) |
| CA (1) | CA3001654A1 (enExample) |
| HK (1) | HK1254630A1 (enExample) |
| IL (1) | IL258574B2 (enExample) |
| WO (1) | WO2017081624A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190152A1 (ar) * | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| WO2021060880A1 (ko) * | 2019-09-24 | 2021-04-01 | 마이오텍사이언스 주식회사 | 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물 |
| CA3177632A1 (en) * | 2020-05-15 | 2021-11-18 | Melih ACAR | Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors |
| AU2022207252A1 (en) | 2021-01-13 | 2023-08-03 | Astellas Pharma Inc. | MULTISPECIFIC ANTIBODY BINDING TO ActRIIA, ActRIIB, AND Fn14 |
| WO2025183966A1 (en) | 2024-02-28 | 2025-09-04 | Versanis Bio, Inc. | Actrii antibodies with extended half life |
| US20260199503A1 (en) | 2025-01-10 | 2026-07-16 | Regeneron Pharmaceuticals, Inc. | Glp1r agonist-tethered gdf8 antibody conjugates and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| EP0729471A1 (en) | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| BR9408323A (pt) | 1993-12-17 | 1997-08-19 | Sandoz Ag | Derivados de rapamicina |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| DE69624921T2 (de) | 1995-06-09 | 2003-09-11 | Novartis Ag, Basel | Rapamycinderivate |
| WO1998002441A2 (en) | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
| IL147803A0 (en) | 1999-08-24 | 2002-08-14 | Ariad Gene Therapeutics Inc | 28-epirapalogs |
| US7252821B2 (en) * | 1999-10-08 | 2007-08-07 | Arius Research Inc. | Cancerous disease modifying antibodies |
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| US20070149458A1 (en) | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| US9610327B2 (en) * | 2007-03-06 | 2017-04-04 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| US20090149511A1 (en) * | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
| ES2655877T3 (es) | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
| JP6042801B2 (ja) | 2010-04-27 | 2016-12-14 | ロシュ グリクアート アーゲー | ｍＴＯＲインヒビターとのアフコシル化ＣＤ２０抗体の併用療法 |
| WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| EP2589385A1 (en) * | 2011-11-03 | 2013-05-08 | Fundación Centro Nacional de Investigaciones Oncológicas | Triple combination for the treatment of cancer |
| KR20150136061A (ko) * | 2013-02-01 | 2015-12-04 | 산타 마리아 바이오테라퓨틱스, 인코포레이티드 | 대상에 항-액티빈-a 화합물의 투여 |
| EP3100056A2 (en) * | 2014-01-27 | 2016-12-07 | Novartis AG | Biomarkers predictive of muscle atrophy, method and use |
| TW201622746A (zh) * | 2014-04-24 | 2016-07-01 | 諾華公司 | 改善或加速髖部骨折術後身體復原之方法 |
-
2016
- 2016-11-09 US US15/774,327 patent/US11357851B2/en active Active
- 2016-11-09 HK HK18113597.0A patent/HK1254630A1/zh unknown
- 2016-11-09 AU AU2016352806A patent/AU2016352806A1/en not_active Abandoned
- 2016-11-09 IL IL258574A patent/IL258574B2/en unknown
- 2016-11-09 KR KR1020187013052A patent/KR102764084B1/ko active Active
- 2016-11-09 CA CA3001654A patent/CA3001654A1/en active Pending
- 2016-11-09 CN CN201680065806.6A patent/CN109069467B/zh active Active
- 2016-11-09 WO PCT/IB2016/056744 patent/WO2017081624A1/en not_active Ceased
- 2016-11-09 EP EP16795436.1A patent/EP3373927A1/en active Pending
- 2016-11-09 JP JP2018524218A patent/JP7841838B2/ja active Active
-
2019
- 2019-09-12 AU AU2019229380A patent/AU2019229380A1/en not_active Abandoned
-
2021
- 2021-05-03 AU AU2021202757A patent/AU2021202757B2/en active Active
-
2022
- 2022-05-06 US US17/738,846 patent/US20220265823A1/en not_active Abandoned
-
2023
- 2023-06-29 JP JP2023106553A patent/JP2023156274A/ja active Pending
- 2023-07-31 AU AU2023210543A patent/AU2023210543B2/en active Active